Clinical Trials Directory

Trials / Completed

CompletedNCT03523182

Spirulina Supplementation and Infant Growth, Morbidity and Motor Development

Promoting Spirulina Production and Utilization in Luapula Province of Zambia

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
501 (actual)
Sponsor
Programme Against Malnutrition · Academic / Other
Sex
All
Age
6 Months – 18 Months
Healthy volunteers
Accepted

Summary

Background: In developing countries, micronutrient deficiency in infants is associated with growth faltering, morbidity, and delayed motor development. One of the potentially low-cost and sustainable solutions is to use locally producible food for the home fortification of complementary foods. Objective: The objectives are to test the hypothesis that locally producible spirulina platensis supplementation would achieve the following: 1) increase infant physical growth; 2) reduce morbidity; and 3) improve motor development. Design: 501 Zambian infants are randomly assigned into a control (CON) group or a spirulina (SP) group. Children in the CON group (n=250) receive a soya-maize-based porridge for 12 months, whereas those in the SP group (n=251) receive the same food but with the addition of spirulina. The change in infants' anthropometric status, morbidity, and motor development over 12 months are assessed.

Detailed description

Micronutrient deficiency in the infancy is associated with growth faltering, morbidity, and delayed motor development, and is common in developing countries where the food available for infants has low micronutrient density. A low-cost and sustainable way to address this problem is to utilize locally producible foods rich in multi-micronutrients as home supplements to complementary food. Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa. It contains a high percentage of protein, and is rich in multiple micronutrients know to support infant growth such as beta carotene, B vitamins, and minerals such as calcium, iron, magnesium, manganese, potassium, and zinc. The cost of producing spirulina is much lower than that of producing other comparably protein-rich foods, such as soya beans and beef, and therefore may potentially sustainably meet the nutritional demands of African infants. Our objective is to assess the acceptability and effects of spirulina supplementation on growth, incidence of morbidity, and level of motor development in infants in Zambia. The testable hypothesis is that spirulina supplementation for 12 months would increase infant height, reduce the incidence of morbidity, and reduce time taken to achieve motor development milestones (ability to walk unassisted). This study is conducted from April 2015 to April 2016 in the form of an open-labeled randomized control trial, and involves in a spirulina-fed treatment (SP) group and a control (CON) group. 501 Zambian infants are randomly assigned into a control (CON) group or a spirulina (SP) group. Children in the CON group (n=250) receive a soya-maize-based porridge for 12 months, whereas those in the SP group (n=251) receive the same food but with the addition of spirulina. The change in infants' anthropometric status, morbidity, and motor development over 12 months are assessed. Amendment: the study period has been extended by 4 months. Without no-intervention period, monthly supplementation was restarted in study are.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSpirulinaArthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa. Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina. We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend.
DIETARY_SUPPLEMENTControlChildren receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.

Timeline

Start date
2015-03-01
Primary completion
2016-04-30
Completion
2018-01-30
First posted
2018-05-14
Last updated
2019-02-11

Locations

1 site across 1 country: Zambia

Source: ClinicalTrials.gov record NCT03523182. Inclusion in this directory is not an endorsement.